洛基維馬
Lokivetmab 是一種**犬源化單株抗體 (mAb)**，專門設計用於標靶並中和**犬白細胞介素-31 (IL-31)**。主要用於治療犬異位性皮膚炎的臨床症狀，能顯著緩解搔癢並具有抗發炎特性。 > **臨床提示：** 作為一種高度標靶的生物療法，Lokivetmab 不具有傳統療法（如皮質類固醇或環孢素）所伴隨的廣泛免疫抑制副作用。
作用機制: Lokivetmab specifically binds to and neutralizes **canine interleukin-31 (IL-31)**, a key cytokine involved in the itch sensation. * **IL-31** → Blocked from binding to its co-receptor * **Cell signalling** → Inhibited * **Result** → Relief from atopic dermatitis-related pruritus and reduction of inflammation.
給藥途徑
禁忌症
- Known hypersensitivity to the active substance or excipients
- Use in species other than dogs
不良反應
- Generally well tolerated
- Rare hypersensitivity reactions or injection site pain
監測
- Clinical response to pruritus and skin inflammation
- Signs of hypersensitivity post-injection
過量
Overdoses are generally well tolerated due to the targeted nature of the monoclonal antibody, though the risk of immune-mediated reactions may theoretically increase. No specific antidote is required; treat symptomatically if adverse effects occur.
VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用,不能取代專業判斷或廠方最新藥品說明書。